Wataru Okamoto

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

Wataru Okamoto

Aug 11, 2024, 12:56 | Insight

Trastuzumab Deruxtecan in HER2–Expressing BTC - Key points by Arndt Vogel

Arndt Vogel shared a post on X: "Trastuzumab Deruxtecan in HER2–Expressing BTC published in Journal of…

Aug 9, 2024, 02:19 | Blog

Activity of T-DXd in HER2-expressing Biliary Tract Cancer

Paolo Tarantino shared on X: "Activity of T-DXd in HER2-expressing BTC published in Journal of Clinical…

Aug 7, 2024, 16:01 | Insight

Piotr Wysocki: Trastuzumab Deruxtecan Shows Promise in Treating HER2-Positive Biliary Tract Cancer

Piotr Wysocki recently shared on LinkedIn: "A recent phase II clinical trial conducted across five…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023